Zimmer Biomet Holdings, Inc.’s Stock Price Drops to $104.47, Marking a Significant 8.74% Decline

Zimmer Biomet Holdings, Inc. (ZBH)

104.47 USD -10.01 (-8.74%) Volume: 4.9M

Zimmer Biomet Holdings, Inc.’s stock price is currently at 104.47 USD, experiencing a significant decrease of -8.74% this trading session, with a trading volume of 4.9M. The company’s stock has shown a year-to-date percentage change of -14.16%, indicating a challenging financial year for ZBH.

Latest developments on Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings stock price took a hit today after the medtech firm warned of a potential revenue impact from a software switch. This news comes after the company appointed David DeMartino as the new Senior Vice President of Investor Relations. The stock fell further on a surprise hit to 2024 sales, causing shares to gap down to $114.48. Despite these challenges, analysts are closely watching the company’s performance, with 14 analyst ratings providing insights into Zimmer Biomet’s future trajectory. With investors closely monitoring the stock, Zimmer Biomet Holdings is poised ahead of its Q2 earnings announcement.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Zimmer Biomet Holdings has a positive long-term outlook. With high scores in Value and Momentum, the company is seen as a strong investment option. This indicates that Zimmer Biomet Holdings is considered to have good value relative to its price and is showing positive momentum in its market performance.

Zimmer Biomet Holdings also received moderate scores in Dividend and Growth, suggesting steady dividend payments and potential for growth. However, the company scored lower in Resilience, indicating some vulnerability to market fluctuations. Overall, Zimmer Biomet Holdings is viewed positively for its value and momentum, making it a potentially attractive choice for investors looking for long-term growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma